Abstract
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance is a major challenge in non–small cell lung cancer (NSCLC). Recently, one study showed that stress hormones promote EGFR inhibitor resistance which may be reversed by combinations of β-blockers with EGFR TKI. This study aims to determine the outcomes of lung cancer patients treated with EGFR-TKI and β-blockers in large database.
Methods: Taiwan National Health Insurance Research Database provided a lung cancer database including 143760 lung cancer patients from January 1, 1996 to December 31, 2013. There were 13585 lung cancer patients treated with EGFR-TKI between January 2009 to June 2013. We use the drug code to identify lung cancer patients with hypertension (HTN) who treated with β-blockers and analyzed the progression free survival (PFS) and overall survival (OS).
Results: There were 11832 patients had HTN under EGFR-TKI therapy and 425 of them used β-blockers. Death was noted in 7354 (62.15%) patients with HTN and 909 (51.9%) patients without HTN. Patients without HTN had significant better PFS and OS than those with HTN (267 versus 239 days, p < 0.0001; 513 versus 436 days, p < 0.0001). In the β-blocker group, the median PFS was 511 (95% C. I, 450-565) days, which was significant longer than of both HTN and non-HTN patients. The median OS of β -blocker group was 703 (95% C. I, 654-815) days and was also the longest between groups.
Conclusions: Concomitant use of β-blockers and EGFR-TKI had better prognosis in NSCLC patients. β-blockers may be considered as an essential therapy for HTN in patients who treated with EGFR-TKI.
Footnotes
Cite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA2855.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2018